Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

(Very Positive)

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) reported that on August 1, 2026, it granted stock options to ten newly hired non-executive employees to purchase an aggregate of 277,500 common shares under the 2026 Inducement Plan, as material inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have a per-share exercise price of $0.535, equal to the July 31, 2026 closing price of Invivyd’s stock. Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments, subject to continued service. The options have a 10-year term and remain subject to the plan’s terms.

Market Context

The prior inducement-grant release, news_id 1077476, recorded a 4.61% 24-hour reaction. The active S...

Analysis

The prior inducement-grant release, news_id 1077476, recorded a 4.61% 24-hour reaction. The active S-3 shelf and moderate short positioning add financing and volatility context; future award frequency and size remain observable.

Key Figures

Grant Date: August 1, 2026 Employees: 10 employees Option Shares: 277,500 shares +4 more

7 metrics

Grant Date August 1, 2026 Employee option grants

Employees 10 employees Newly hired non-executive employees

Option Shares 277,500 shares Aggregate common stock options granted

Exercise Price $0.535 per share Equal to the July 31, 2026 closing price

Vesting Period 4 years Option vesting schedule

Initial Vesting 25% Vests on the first anniversary of the employee’s start date

Option Term 10 years Term of each option

Historical Context

5 past events · Latest: Jul 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 06	EUA termination notice	Negative	-6.7%	FDA notice set PEMGARDA EUA termination for June 29, 2027
Jul 02	Inducement grants	Neutral	+4.6%	Fourteen employees received options for 493,000 shares at $0.8544 each
Jun 16	Enrollment completion	Positive	+2.7%	Company completed Phase 3 LIBERTY enrollment; topline data were expected in Q3 2026
Jun 09	First trial dosing	Positive	-2.9%	LIBERTY dosed its first participants in a Phase 3 COVID-19 prevention trial
Jun 03	Inducement grants	Neutral	-3.5%	Seventeen employees received options for 513,500 shares under the 2026 Inducement Plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical inducement-grant releases had mixed reactions, while the EUA termination announcement aligned with a decline.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/04/2026 - 07:01 AM

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an aggregate of 277,500 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.535, representing the closing price of Invivyd’s common stock on July 31, 2026, the last trading date prior to the date of grant. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

What stock options did Invivyd (NASDAQ: IVVD) grant on August 1, 2026?

Invivyd granted options for an aggregate 277,500 common shares to ten new non-executive employees. According to Invivyd, these options were issued as material inducement awards under the 2026 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new Invivyd (IVVD) inducement stock options?

The new Invivyd inducement stock options have a per-share exercise price of $0.535. According to Invivyd, this price equals the closing market price of its common stock on July 31, 2026, the last trading day before the grant date.

How do the Invivyd (IVVD) August 2026 inducement options vest for new employees?

The Invivyd inducement options vest over four years, with 25% vesting on the first employment anniversary. According to Invivyd, the remaining 75% vests in equal monthly installments thereafter, subject to each employee’s continuous service with the company.

What is the term of Invivyd’s August 2026 inducement stock options (IVVD)?

Invivyd’s August 2026 inducement stock options have a 10-year term from the grant date. According to Invivyd, the options remain subject to all provisions of the Invivyd 2026 Inducement Plan throughout this term.

Under which plan were the Invivyd (IVVD) August 2026 inducement options granted?

The August 2026 inducement options were granted under the Invivyd 2026 Inducement Plan. According to Invivyd, these awards were specifically structured to comply with Nasdaq Listing Rule 5635(c)(4) for material inducement grants to newly hired employees.